

Intact Mass



Chad Eichman, Ph.D.
BioPharm Global Marketing Manager

I need to perform intact mass experimentation, but often I have no idea of what my protein is formulated in. Should I perform a dialysis or spin filtration before analysis?

Whether looking at mAbs or other proteins, formulation buffers often contain matrix interferences. These include the buffer salts themselves (Tris, HEPES, TBS, PBS, CHAPS, etc.) which are all very common storage buffers, and are not compatible with ESI-MS.

Typically, a buffer exchange using dialysis or a spin filtration device is performed. However, one can simply use the reversed phase column for intact mass as an online desalting device. For example, start your method with a 3 minute isocratic wash that goes to waste, or use a diverter valve. This can rid most of the buffer salts that would potentially interfere with the MS analysis.

My spectra for intact mass is horrible and my MS vendor said that it might be chromatography related! What do I do?

Unlike other forms of chromatography, like impurity profiling by reversed phase, for intact mass the goal is for good peak shape, allowing the high-resolution MS to scan under the peak. Although this might seem straightforward, any separation with proteins is never as easy as it seems, so optimization might be necessary for proteins that behave in unexpected ways.

Because intact mass works optimally with proteins unfolded and denatured, high heat is mandatory for optimal peak shape.

70-90 °C is required for most applications, especially mAbs which require a fair amount of heat for denaturation.

The other consideration is solvent composition. For most silica-based columns, even a low surface area core-shell media, isopropanol (IPA) might be required for optimal peak shape. Not only does IPA have a stronger elution strength in reversed phase than the commonly used acetonitrile, but alcohols do better at destabilizing the hydrophobic interactions that keep proteins folded.

Finally, if a clean spectra still cannot be obtained, try deglycosylation of the protein, as this will simplify the spectra. If spectra still cannot be obtained, this may be sample related and the protein may be too degraded for MS analysis.

What should I do about carryover in my intact mass separation?

Some proteins, especially mAbs and ADCs, can be quite hydrophobic and “memory effect” might be observed even with an optimized gradient and a column with good surface chemistry and particle morphology for intact mass. Carryover by memory effect is more pronounced in very sensitive techniques like MS.

One effective way to reduce carryover is to implement a “zig zag” gradient (e.g. short, repeated gradients of 15-85% B) after the initial wash to ensure no carryover is observed. If carryover is still observed, it could be system related.

Product Ordering Information

bioZen™ Products - Powered by Biocompatible Hardware

bioZen Columns (mm)	Phases							Biocompatible Guard Cartridges*	
	50 x 2.1	100 x 2.1	150 x 2.1	250 x 2.1	50 x 4.6	150 x 4.6	300 x 4.6	for 2.1 mm	for 4.6 mm
bioZen 2.6 µm Glycan	—	00D-4773-AN	00F-4773-AN	—	—	—	—	AJO-9800	—
bioZen 1.6 µm Peptide PS-C18	00B-4770-AN	—	00F-4770-AN	—	—	—	—	AJO-9803	—
bioZen 3 µm Peptide PS-C18	—	—	—	—	00B-4771-E0	00F-4771-E0	—	—	AJO-7606
bioZen 1.7 µm Peptide XB-C18	00B-4774-AN	—	00F-4774-AN	—	—	—	—	AJO-9806	—
bioZen 2.6 µm Peptide XB-C18	00B-4768-AN	—	00F-4768-AN	00G-4768-AN	00B-4768-E0	00F-4768-E0	—	AJO-9806	AJO-9808
bioZen 3.6 µm Intact C4	00B-4767-AN	—	00F-4767-AN	—	00B-4767-E0	00F-4767-E0	—	AJO-9809	AJO-9811
bioZen 3.6 µm Intact XB-C8	00B-4766-AN	—	00F-4766-AN	—	00B-4766-E0	00F-4766-E0	—	AJO-9812	AJO-9814
bioZen 1.8 µm SEC-2	—	—	—	—	—	00F-4769-E0	00H-4769-E0	—	AJO-9850
bioZen 1.8 µm SEC-3	—	—	—	—	—	00F-4772-E0	00H-4772-E0	—	AJO-9851

*AJO-7606 requires guard holder KJO-4282. All other guard cartridges require guard holder AJO-9000.



Have Questions? Visit:
www.phenomenex.com/bioZen
 We're here to help!

guarantee

If bioZen columns in this technical note do not provide at least equivalent separations as compared to a competing column of the same phase, particle size, and dimensions, return the column with the comparative data within 45 days for a FULL REFUND.

Australia

t: +61 (0)2-9428-6444
 f: +61 (0)2-9428-6445
auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
 f: +43 (0)1-319-1300
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
 t: +32 (0)2 511 8666 (Dutch)
 f: +31 (0)30-2383749
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
 f: +1 (310) 328-7768
info@phenomenex.com

China

t: +86 400-606-8099
 f: +86 (0)22 2532-1033
phen@agela.com

Denmark

t: +45 4824 8048
 f: +45 4810 6265
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
 f: +45 4810 6265
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
 f: +33 (0)1 30 09 21 11
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
 f: +49 (0)6021-58830-11
anfrage@phenomenex.com

India

t: +91 (0)40-3012 2400
 f: +91 (0)40-3012 2411
indiainfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
 f: +44 1625-501796
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
 f: +39 051 6327555
italiainfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
 f: +31 (0)30-2383749
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
 f: 001-310-328-7768
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
 f: +31 (0)30-2383749
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
 f: +64 (0)9-4780952
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
 f: +45 4810 6265
nordicinfo@phenomenex.com

Portugal

t: +351 221 450 488
 f: +34 91-413-2290
ptinfo@phenomenex.com

Spain

t: +34 91-413-8613
 f: +34 91-413-2290
esinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
 f: +45 4810 6265
nordicinfo@phenomenex.com

Switzerland

t: +41 61 692 20 20
 f: +41 61 692 20 22
swissinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
 f: +44 (0)1625-501796
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
 f: +1 (310) 328-7768
info@phenomenex.com

All other countries Corporate Office USA

t: +1 (310) 212-0555
 f: +1 (310) 328-7768
info@phenomenex.com

Terms and Conditions
 Subject to Phenomenex Standard Terms & Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

bioZen is a trademark of Phenomenex.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2018 Phenomenex, Inc. All rights reserved.

 **phenomenex**
 ...breaking with tradition™